The U.S. Food and Drug Administration objected to an application from Charlotte’s Web Holdings Inc. for a CBD product to be sold as a dietary ingredient, leaving a cloud of uncertainty over the booming industry for the cannabis-derived substance.
View the full article here: https://fortune.com/2021/08/11/fda-cbd-dietary-supplement-charlottes-web-holdings/
IASIC commends the FDA to sticking to science. While CBD is sold as a healthy supplement, FDA labeling of approved CBD tells a different story. CBD interacts with over 500 medications, can cause liver damage and mental health symptoms. Any time medications are recommended there must be a risk/ benefit calculation. For CBD it does not always add up. Please see the IASIC library for information on CBD and harms of cannabis.